General Information of the Drug (ID: M6APDG01084)
Name
T-5224
Synonyms
AKOS003047196; T5224
    Click to Show/Hide
Status
Discontinued in Phase 2
Structure
Formula
C29H27NO8
InChI
1S/C29H27NO8/c31-24-15-21(37-20-3-1-2-4-20)8-10-22(24)28(34)19-6-11-25(18(14-19)7-12-27(32)33)36-16-17-5-9-23-26(13-17)38-30-29(23)35/h5-6,8-11,13-15,20,31H,1-4,7,12,16H2,(H,30,35)(H,32,33)
InChIKey
DALCQQSLNPLQFZ-UHFFFAOYSA-N
PubChem CID
23626877
TTD Drug ID
D02LCL
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Transcription factor AP-1 (JUN)
Protein virilizer homolog (VIRMA)
In total 1 mechanisms lead to this potential drug response
Response Summary Transcription factor AP-1 (JUN) is a therapeutic target for T-5224. The Protein virilizer homolog (VIRMA) has potential in affecting the response of T-5224 through regulating the expression of Transcription factor AP-1 (JUN). [1], [2]
References
Ref 1 KIAA1429 regulates cell proliferation by targeting c-Jun messenger RNA directly in gastric cancer. J Cell Physiol. 2020 Oct;235(10):7420-7432. doi: 10.1002/jcp.29645. Epub 2020 Feb 13.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)